Praxis Precision Medicines forecasts $10 billion in peak sales for ulixacaltamide
PRAX•Praxis Precision Medicines outlined more than $20 billion in potential peak sales across its sales guidance and pipeline, including $10 billion for ulixacaltamide. It also forecast peak sales of $5 billion for relutrigine, $4 billion for vormatrigine and $1 billion for elsunersen.
1. Peak sales estimates
Praxis Precision Medicines outlined more than $20 billion in potential peak sales across its sales guidance and pipeline. Its peak sales guidance is $10 billion for ulixacaltamide, $5 billion for relutrigine, $4 billion for vormatrigine and $1 billion for elsunersen. The brief estimates that 9 million Americans live with essential tremor.
